Education
About Us
Working with TipRanks
Follow Us
LivaNova PLC (LIVN)
NASDAQ:LIVN
LIVN Analyst Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
LIVN Stock 12 Month Forecast
Average Price Target
$64.14
▲(42.00%Upside)
| Highest Price Target$79.00 | Average Price Target$64.14 | Lowest Price Target$55.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$50
Hold
10.69%
Upside
Reiterated
06/12/25
LivaNova's stock score reflects strong revenue growth and technical momentum as key positives. However, profitability challenges and valuation concerns weigh on the score. Positive earnings call sentiment and clinical trial successes provide a promising outlook, though legal liabilities present risks.
Jefferies
$79
Buy
74.89%
Upside
Reiterated
06/06/25
Barclays
$55
Hold
21.76%
Upside
Reiterated
06/05/25
Piper Sandler
$75
Buy
66.04%
Upside
Reiterated
05/22/25
Wolfe Research
$60
Buy
32.83%
Upside
Upgraded
05/19/25
Needham
$64
Buy
41.69%
Upside
Reiterated
05/13/25
Mizuho Securities
$50→$55
Buy
21.76%
Upside
Reiterated
05/08/25
Robert W. Baird
$55→$61
Buy
35.05%
Upside
Reiterated
05/08/25
Goldman Sachs
$55
Buy
21.76%
Upside
Reiterated
03/09/25
Positive Outlook for LivaNova Driven by Product Upgrades and Market ExpansionWe hosted Vlad Makatsaria (CEO), Alex Shvartsburg (CFO), and Briana Gotlin (VP , Investor Relations) for investor meetings in Chicago, where key focus areas included: (1) core business growth trajectory; (2) pipeline development; (3) operating margin expansion opportunities; and (4) capital allocation priorities. These investor meetings followed the company’s 4Q24 results and introduction of 2025 guidance with LIVN shares underperforming YTD (-16% vs. the Russel 2000 -7%). Investor debate around the stock has intensified surrounding underlying durability of the base business, path to realizing positive returns from pipeline investments in new growth categories, and the corresponding impact on the P&L, in our view. Fundamental dynamics also continue to face the overhang of outstanding litigation (SNIA), where the company expects to have a more detailed update later in 1H25.
Stifel Nicolaus
$72→$60
Buy
32.83%
Upside
Reiterated
02/25/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$50
Hold
10.69%
Upside
Reiterated
06/12/25
LivaNova's stock score reflects strong revenue growth and technical momentum as key positives. However, profitability challenges and valuation concerns weigh on the score. Positive earnings call sentiment and clinical trial successes provide a promising outlook, though legal liabilities present risks.
Jefferies
$79
Buy
74.89%
Upside
Reiterated
06/06/25
Barclays
$55
Hold
21.76%
Upside
Reiterated
06/05/25
Piper Sandler
$75
Buy
66.04%
Upside
Reiterated
05/22/25
Wolfe Research
$60
Buy
32.83%
Upside
Upgraded
05/19/25
Needham
$64
Buy
41.69%
Upside
Reiterated
05/13/25
Mizuho Securities
$50→$55
Buy
21.76%
Upside
Reiterated
05/08/25
Robert W. Baird
$55→$61
Buy
35.05%
Upside
Reiterated
05/08/25
Goldman Sachs
$55
Buy
21.76%
Upside
Reiterated
03/09/25
Positive Outlook for LivaNova Driven by Product Upgrades and Market ExpansionWe hosted Vlad Makatsaria (CEO), Alex Shvartsburg (CFO), and Briana Gotlin (VP , Investor Relations) for investor meetings in Chicago, where key focus areas included: (1) core business growth trajectory; (2) pipeline development; (3) operating margin expansion opportunities; and (4) capital allocation priorities. These investor meetings followed the company’s 4Q24 results and introduction of 2025 guidance with LIVN shares underperforming YTD (-16% vs. the Russel 2000 -7%). Investor debate around the stock has intensified surrounding underlying durability of the base business, path to realizing positive returns from pipeline investments in new growth categories, and the corresponding impact on the P&L, in our view. Fundamental dynamics also continue to face the overhang of outstanding litigation (SNIA), where the company expects to have a more detailed update later in 1H25.
Stifel Nicolaus
$72→$60
Buy
32.83%
Upside
Reiterated
02/25/25
Best Analysts Covering LivaNova
1 Month
xxx
Success Rate
14/21 ratings generated profit
Average Return
+2.93%
reiterated a xxx
rating 30 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +2.93% per trade.
3 Months
xxx
Success Rate
11/23 ratings generated profit
Average Return
-3.63%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 47.83% of your transactions generating a profit, with an average return of -3.63% per trade.
1 Year
Success Rate
8/21 ratings generated profit
Average Return
-9.94%
reiterated a buy rating 30 days ago
Copying Adam Maeder's trades and holding each position for 1 Year would result in 38.10% of your transactions generating a profit, with an average return of -9.94% per trade.
2 Years
xxx
Success Rate
10/28 ratings generated profit
Average Return
-12.72%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 35.71% of your transactions generating a profit, with an average return of -12.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
LIVN Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
2
4
4
5
4
Buy
8
6
5
7
6
Hold
4
5
4
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
15
13
15
12
Each month's total comprises the sum of three months' worth of ratings.
LIVN Financial Forecast
LIVN Stock Forecast FAQ
What is LIVN’s average 12-month price target, according to analysts?
Based on analyst ratings, LivaNova PLC’s 12-month average price target is 64.14.
What is LIVN’s upside potential, based on the analysts’ average price target?
LivaNova PLC has 42.00% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is LIVN a Buy, Sell or Hold?
LivaNova PLC has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
What is LivaNova PLC’s price target?
The average price target for LivaNova PLC is 64.14. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $79.00 ,the lowest forecast is $55.00. The average price target represents 42.00% Increase from the current price of $45.17.
The highest analyst price target is $79.00 ,the lowest forecast is $55.00. The average price target represents 42.00% Increase from the current price of $45.17.
What do analysts say about LivaNova PLC?
LivaNova PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of LIVN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.